Amgen (AMGN) Tops Q3 EPS by 35c; Raises Outlook

Go back to Amgen (AMGN) Tops Q3 EPS by 35c; Raises Outlook

Amgen (AMGN) Sees Double-Digit EPS Growth Out to 2018; UBS Raises Price target to $180

October 29, 2015 10:46 AM EDT

UBS reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target to $180.00 (from $168.00), following the company's 3Q earnings results. AMGN reported a $0.34 EPS beat on another strong quarter of key product growth and cost controls. Management still sees double-digit EPS growth out to 2018.

Analyst Matthew Roden commented, "AMGN reported a $0.34 EPS beat (14% over consensus) on another strong quarter of... More